Brought to you by 
Neurotrope gets more bryostatin IP from Stanford University
02 Feb 2023
Executive Summary
Stanford University licensed therapeutics and diagnostics start-up Neurotrope Inc. exclusive global rights to manufacture and market bryostatin analogs, or bryologs, for neurodegenerative diseases (including Fragile X, traumatic brain injury, and Alzheimer’s), lysosomal storage disorders, stroke, and cardioprotection. The transaction includes three issued US patents, one pending US patent, and related technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Manufacturing or Supply
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neurotrope gets more bryostatin IP from Stanford University
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice